Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

Salvatore Petta, Marco Marzioni, Pierluigi Russo, Alessio Aghemo, Alfredo Alberti, Antonio Ascione, Andrea Antinori, Raffaele Bruno, Savino Bruno, Antonio Chirianni, Giovanni Battista Gaeta, Edoardo G Giannini, Manuela Merli, Vincenzo Messina, Simona Montilla, Carlo Federico Perno, Massimo Puoti, Giovanni Raimondo, Maria Rendina, Francesca Ceccherini Silberstein, Erica Villa, Anna Linda Zignego, Luca Panì, Antonio Craxì, on behalf of the ABACUS study group* and the AIFA team*

Summary

Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decomposition while approval of these regimens was pending in Italy.

Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decomposition were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with HCV genotype 1b infection) or 24 weeks (patients with HCV genotype 1a infection). Patients with HCV genotype 4 infection were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once per day for 24 weeks. All patients were given weight-based ribavirin. The primary efficacy endpoint was sustained virological response at week 12 after the end of treatment (SVR12), analysed by intention-to-treat. Univariate and multivariate logistic regression analyses were used to identify baseline characteristics associated with SVR12. Adverse events were recorded throughout the study.

Findings 728 (96%) of 762 patients with cirrhosis who were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12. Logistic regression analyses identified that bilirubin concentrations of less than 2 mg/dL were associated with SVR12 (odds ratio [OR] 4·76 [95% CI 1·83–12·3; p=0.001). 166 (23%) of 734 patients included in safety analyses had an adverse event. 25 (3%) patients discontinued treatment because of adverse events. Asthenia was the most commonly reported adverse event, occurring in 36 (5%) patients.

Interpretation Our findings suggest that the safety and effectiveness of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 infection and cirrhosis at high risk of decomposition in a real-life setting are similar to those reported in clinical trials. The concordance with clinical trials provides reassurance that the reported efficacy of this treatment in clinical trials will translate to its use in routine clinical practice.

Funding Dipartimento Biomedico di Medicina Interna e Specialistica dell’Università di Palermo.

Introduction European guidelines on the treatment of chronic hepatitis C virus (HCV) infection regard patients with cirrhosis as a high-priority population for treatment.1 In Europe, the all-oral, three direct-acting antiviral (DAA) regimen of ombitasvir, paritaprevir, and the pharmacokinetic enhancer ritonavir, with dasabuvir, with or without ribavirin is approved for the treatment of HCV genotype 1 infection, whereas the two DAA regimen of ombitasvir, paritaprevir, and ritonavir, plus ribavirin is approved for the treatment of HCV genotype 4 infection.2-3

In previously untreated or treated patients with compensated cirrhosis, 114 (94%) of 121 patients with genotype 1a infection had a sustained virological response at week 12 after the end of treatment (SVR12) with ombitasvir, paritaprevir, and ritonavir, with dasabuvir plus ribavirin for 24 weeks, and 60 (100%) of 60 patients with genotype 1b infection who were given a 12 week regimen of ombitasvir, paritaprevir, and ritonavir, with dasabuvir, without ribavirin achieved SVR12.2-3 In previously untreated or treated patients with genotype 4 infection and compensated cirrhosis, 60 (98%) of 61 patients who had 16 weeks of treatment and 57 (97%) of 59 patients and 30 (97%) of 31 patients, who had 12 weeks of treatment with the all-oral two-DAA regimen of ombitasvir, paritaprevir, and ritonavir, plus ribavirin achieved SVR12.2-3 The safety profiles of the ombitasvir, paritaprevir, and ritonavir, plus ribavirin regimens with or without dasabuvir in patients with compensated cirrhosis were similar to those in patients without cirrhosis.2-3

*Members listed in the appendix

Published Online April 10, 2017
http://dx.doi.org/10.1016/S2468-1253(17)30048-1

This online publication has been corrected. The corrected version first appeared at thelancet.com/gastrohep on May 5, 2017

* Members listed in the appendix
Compassionate-use programmes for DAAs can provide access to drugs that have yet to be approved for high-priority patients with advanced, compensated cirrhosis who are at high risk of decompensation across a short timespan. Furthermore, these programmes provide additional early data on the effectiveness and safety of DAA regimens in general clinical practice and early experience of using new treatment regimens. With the support of the Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA), we did the AIFA-Based Associazione Italiana per lo Studio del Fegato (AISF) Compassionate Use Study (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for high-priority patients with genotype 1 HCV infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for high-priority patients with genotype 4 infection while approval of these regimens was pending in Italy. We report the efficacy and safety of ombitasvir, paritaprevir, and ritonavir, plus ribavirin in patients with HCV genotype 4 infection, published between Jan 1, 2014, and Dec 31, 2016. Only trials that included patients with compensated cirrhosis were selected. Three randomised, open-label trials and one single-arm, open-label trial were identified that met the criteria. In treatment-naive or treatment-experienced patients with compensated cirrhosis, treatment with ombitasvir, paritaprevir, and ritonavir, plus dasabuvir resulted in sustained virological response at week 12 after the end of treatment (SVR12) in 94% of patients with HCV genotype 1a infection who were given a 24 week regimen with ribavirin and 100% of patients with HCV genotype 1b infection who were given a 12 week regimen without ribavirin.

In treatment-naive or treatment-experienced patients with HCV genotype 4 infection and compensated cirrhosis, the all-oral two-DAA regimen of ombitasvir, paritaprevir, and ritonavir, plus ribavirin resulted in 100% of patients achieving SVR12 after 16 weeks of treatment and 97% of patients achieving SVR12 after 12 weeks of treatment.

Research in context

Evidence before this study

We searched PubMed with search terms “ombitasvir”, “paritaprevir”, “dasabuvir”, “genotype 1”, “genotype 4”, and “cirrhosis” for trials of the all-oral three direct-acting antiviral (DAA) regimen of ombitasvir, paritaprevir, and ritonavir, with dasabuvir, with or without ribavirin in patients with hepatitis C virus (HCV) genotype 1 infection and the all-oral two-DAA regimen of ombitasvir, paritaprevir, and ritonavir, plus ribavirin in patients with HCV genotype 4 infection, published between Jan 1, 2014, and Dec 31, 2016. Only trials that included patients with compensated cirrhosis were selected. Three randomised, open-label trials and one single-arm, open-label trial were identified that met the criteria. In treatment-naive or treatment-experienced patients with compensated cirrhosis, treatment with ombitasvir, paritaprevir, and ritonavir, plus dasabuvir resulted in sustained virological response at week 12 after the end of treatment (SVR12) in 94% of patients with HCV genotype 1a infection who were given a 24 week regimen with ribavirin and 100% of patients with HCV genotype 1b infection who were given a 12 week regimen without ribavirin.

Methods

Study design

ABACUS was a prospective, longitudinal, observational study. ABACUS was not a clinical trial, but a compassionate-use programme, so there was no planned number of patients or sites. The compassionate-use programme was initiated by AbbVie (Campoverde, Italy) on March 17, 2014. Recruitment was stopped on May 28, 2015, when ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin received marketing approval by AIFA. Patients were recruited at 176 sites in Italy via a network established by AISF and AIFA. The data analysis cutoff was Feb 1, 2016. Patients were treated according to the European guidelines that were in use at the time of the study. Briefly, patients with HCV genotype 1 infection who had cirrhosis were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with genotype 1b HCV infection) or 24 weeks (patients with genotype 1a HCV infection). Patients with genotype 4 infection had cirrhosis were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) for 24 weeks (appendix p 4). Ombitasvir, paritaprevir, ritonavir, and dasabuvir were provided by AbbVie. All patients were given weight-based doses of ribavirin (1000 mg for patients <75 kg, or 1200 mg for patients ≥75 kg) as recommended by the drug label. Blood transfusions and use of erythropoietin were permitted if deemed medically necessary.

The study was done in accordance with the International Conference on Harmonisation guidelines, applicable regulations at each study site, and the principles of the Declaration of Helsinki. Local ethics approval was obtained at each site.

Patients

The ABACUS compassionate-use programme provided treatment access for patients with HCV genotype 1 or 4 infection who had compensated cirrhosis and were at high risk of decompensation. High risk of decompensation was defined as clinical features suggestive of rapidly progressive fibrosis or impending decompensation (eg, a rapid decline in platelets, albumin concentration, or both) with previous signs or history of
decompensation, or with rapid progression from histologically or clinically proven chronic HCV infection without cirrhosis to clinically diagnosed cirrhosis. All patients had Child-Pugh class A cirrhosis at the time of enrolment, but those with a history of decompensation were not excluded, and a change in Child-Pugh class could occur between enrolment and start of treatment. Diagnosis of cirrhosis at baseline was made by meeting at least one of the following criteria: histology from a liver biopsy, a FibroScan (Echosens, Paris, France) result of more than 14.6 kPa, a platelet count of less than 100 000 cells per µL, or the presence of oesophageal varices. Patients could be treatment naive (defined as never having had HCV treatment), or treatment experienced (defined as having previous treatment with interferon-based therapy, with or without ribavirin, and being a non-responder or a relapser, or interferon-intolerant).

All patients in the study provided written informed consent before any study-specific procedures were carried out.

Efficacy and safety assessments

Efficacy and safety assessments were at the discretion of the investigators because this was a compassionate use programme and not a clinical trial. HCV RNA testing was done at the local laboratory at each site. However, investigators were requested to do laboratory assessments, including international normalised ratio (INR), albumin concentration, bilirubin concentration, alanine aminotransferase (ALT) concentration, and haemoglobin concentration at baseline, at treatment weeks 2 and 4, every 4 weeks during treatment thereafter, and at week 12 after treatment. We assessed HCV RNA concentration at baseline, week 4 of treatment, end of treatment, and week 12 after treatment. We recorded data on adverse events throughout the study. Patient visits and follow-up, as well as laboratory testing, were done according to the sites’ local standards. Laboratory and safety data were reported on an ongoing basis on a spreadsheet to the principal investigator. All clinicians were invited to contribute to data collection, but not all clinicians contributed.

Outcomes

The primary efficacy endpoint was the percentage of patients achieving an HCV RNA concentration of less than 25 IU/mL 12 weeks after the end of therapy—ie, SVR12—by intention to treat. Secondary endpoints were the percentage of patients with virological breakthrough during treatment or relapse after treatment; effect of antiviral therapy on markers of liver function, such as INR, albumin concentration, and bilirubin concentration; safety events consistent with hepatic decompensation; and deaths during the study. We defined virological breakthrough during treatment as a confirmed HCV RNA concentration of 25 IU/mL or higher after achieving an HCV RNA concentration of lower than 25 IU/mL. We defined virological relapse as a confirmed HCV RNA concentration of 25 IU/mL or higher between the end of treatment and 12 weeks after the last dose of study drug in patients who had an HCV RNA concentration of lower than 25 IU/mL at the final visit during the treatment period.

Statistical analysis

We tested changes in biochemical parameters over time by means of a paired two-sample t test for comparisons that involved only two timepoints and by a linear mixed-effect regression model over time (with an intercept random effect for each patient) for comparisons that involved more than two timepoints. All analyses were done using IBM SPSS (version 18). We did efficacy analyses for patients with cirrhosis in the intention-to-treat (ITT) population (defined as all enrolled patients who were given at least one dose of study drug), and the per-protocol population (defined as all enrolled patients who completed treatment or discontinued treatment due to virological breakthrough).

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Patients were enrolled in the study between March 17, 2014, and May 28, 2015. 934 patients with cirrhosis were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin. 762 patients were included in the ITT population, 728 were included in the per-protocol population, and 734 were included in the safety population (figure; appendix p 5). Of the 172 patients who were not included in the ITT analysis, 128 were still on treatment or in the follow-up period before the week 12 follow-up visit at the time of the analysis, and clinicians chose not to provide...
data for analysis and dissemination for the remaining 44 patients. Baseline characteristics of patients with cirrhosis included in the study compared with those not included in the analysis were not substantially different. No patients were lost to follow-up. Baseline demographics and disease characteristics are presented in table 1. Previous decompensation was recorded in seven (18%) of 39 patients with Child-Pugh class B cirrhosis. The mean age of patients with Child-Pugh class B cirrhosis was 62.8 years (SD 9.4) and 24 (62%) patients were men. Patients with Child-Pugh class B cirrhosis at baseline were treated at the discretion of the site investigator. All patients with Child-Pugh A were treated. All 39 patients with Child-Pugh class B cirrhosis were included in the ITT population, and 33 of these patients were included in the per-protocol population.

728 (96%) of 762 patients in the ITT population who were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12 (table 2). The proportions of patients achieving SVR12 were similar in centres treating fewer than ten patients compared with centres treating ten or more patients (data not shown). SVR12 rates in treatment history and baseline HCV RNA concentration subgroups did not differ from the overall proportion of patients achieving SVR12 (table 2). The proportion of patients achieving SVR12 did not differ substantially between treatment-naive and treatment-experienced patients in HCV genotype subgroups (appendix p 6). There were significant differences in the proportion of patients achieving SVR12 by HCV genotype 1 subtype in the per-protocol population (genotype 1a 137 [95%] of 144 patients vs genotype 1b 545 [98%] of 554 patients; p=0.02). There was no significant difference in the ITT population (table 2). The proportion of patients achieving SVR12 did not differ substantially by age, sex, or body-mass index (appendix p 7), renal function (appendix p 8), or by baseline FibroScan result (appendix p 9) in the ITT population. Analyses of SVR by age, sex, body-mass index, renal function, and baseline FibroScan score were not done in the per-protocol population. Fewer patients with Child-Pugh class B cirrhosis achieved SVR12 than patients with Child-Pugh A cirrhosis (p=0.0001; appendix p 10); there was no significant difference in SVR rate by MELD score. The proportion of patients achieving SVR12 was lower in patients with markers of more severe liver disease (p=0.01 for platelet count <100,000 cells per μL; p=0.01 for albumin <3.5 g/dL; and p=0.001 for bilirubin ≥2 mg/dL; appendix pp 10–11) by ITT. The proportion of patients achieving SVR12 who had HCV RNA concentrations of 25 IU/mL or lower at week 4 was significantly higher than those with HCV RNA concentrations higher than 25 IU/mL at week 4 (p=0.002; appendix p 12). This was predominantly driven by the subgroup of patients with HCV genotype 1b infection who were given ombitasvir, paritaprevir, ritonavir, with dasabuvir plus ribavirin for 12 weeks. Ribavirin dose had no effect on the proportion of patients achieving SVR12 (appendix p 13).

In the per-protocol population, a lower proportion of patients achieving SVR12 was observed in patients with bilirubin concentration of 2 mg/dL or higher (p=0.003; appendix p 11), but no significant differences in SVR12 were recorded by presence of varices (appendix p 10) or other markers of severe liver disease (appendix p 11).

In the multivariate logistic regression analysis, the only factor with a significant association with SVR12 in the ITT population was a baseline bilirubin concentration of less than 2 mg/dL (odds ratio [OR] 4.76 [95% CI 1.62–14.6]; p=0.005). In the per-protocol population, baseline factors associated with achieving SVR12 were genotype 1b infection (OR 2.97 [95% CI 1.08–8.22]; p=0.03) and bilirubin concentration of less than 2 mg/dL (4.88 [1.62–14.6]; p=0.005). In patients with HCV genotype 1b infection, baseline bilirubin concentration of lower than 2 mg/dL was independently associated with SVR12 (OR 5.09 [95% CI 1.74–14.8]; p=0.003). In patients with HCV genotype 1a infection, SVR12 was marginally, though not significantly, associated with baseline bilirubin concentration of lower than 2 mg/dL (6.70 [0.95–46.9]; p=0.05) and baseline serum albumin concentration of ≥3.5 g/dL or higher (6.98 [1.21–40.2]; p=0.03). There were too few patients with genotype 4 infection for subgroup analysis.
In the ITT population, fewer patients achieved SVR12 who had bilirubin concentrations of 2 mg/dL or higher and albumin concentrations of lower than 3.5 g/dL compared with those with other combinations of bilirubin and albumin values (appendix p 14). In the per-protocol population, the proportion of patients achieving SVR12 was lower in patients with HCV genotype 1a infection and bilirubin concentrations of 2 mg/dL or higher compared with those with HCV genotype 1a infection and bilirubin concentrations lower than 2 mg/dL (appendix p 15).

Of patients who achieved SVR12, markers of liver function significantly improved by week 12 after treatment compared with baseline (appendix p 16). There was no significant difference in INR (p=0.34). Virological breakthrough occurred in four (1%) of 762 patients in the ITT population, whereas virological relapse occurred in 14 (2%) of 762 patients. None of the patients who did not achieve SVR12 had liver decompensation up to 12 weeks after treatment. Most patients with Child-Pugh class B cirrhosis at baseline who achieved SVR12 had an improvement in Child-Pugh score, MELD score, or both (appendix p 17).

ALT concentrations rapidly decreased to normal levels with ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for 12 weeks, and remained at normal levels 12 weeks after treatment (appendix p 18). Bilirubin concentrations were raised at week 2 of treatment, but gradually decreased thereafter, and reached normal levels at week 12 after treatment (appendix p 18). Haemoglobin concentrations decreased with start of treatment, but plateaued at week 4, and returned to baseline values at week 12 after treatment (appendix p 18). Haemoglobin concentrations decreased with start of treatment, but gradually decreased thereafter, and reached normal levels at week 12 after treatment (appendix p 18). Haemoglobin concentrations decreased with start of treatment, but gradually decreased thereafter, and reached normal levels at week 12 after treatment (appendix p 18). Haemoglobin concentrations decreased with start of treatment, but gradually decreased thereafter, and reached normal levels at week 12 after treatment (appendix p 18).
Blood transfusions were given to 14 (2%) patients and occurring in 18 (2%) patients. Severe anaemia was the most commonly reported adverse event, of individual adverse events were low (table 3). Asthenia concentration during treatment and 12 weeks after treatment (appendix p 22). There were no changes in blood glucose concentration during treatment and 12 weeks after treatment (appendix p 24).

166 (23%) of 734 patients had an adverse event. Rates of individual adverse events were low (table 3). Asthenia was the most commonly reported adverse event, occurring in 36 (5%) of patients. Severe anaemia (<8 g/dL haemoglobin) occurred in 18 (2%) patients. Blood transfusions were given to 14 (2%) patients and erythropoietin was given to 27 (4%) patients. Occurrences of hepatic decompensation (four [1%] of 734 patients) and renal failure (two [1%] of 734 patients) were low. 25 (3%) of 734 patients discontinued study drugs due to an adverse event. There were six deaths during the study (table 3). Multivariate logistic regression analysis showed that bilirubin concentration of 2 g/dL or higher was significantly associated with serious adverse events (OR 3.23 [95% CI 1.37–7.69]; p=0.007).

More adverse events took place in patients with Child-Pugh class B cirrhosis than those with Child-Pugh A class cirrhosis (table 3), although the number of patients with Child-Pugh class B cirrhosis in this study was low.

Data are n (%). Most common adverse events were those that occurred in 5% of patients or more in either group, while adverse events of special interest were anaemia (haemoglobin concentration <8 g/dL), hyperbilirubinaemia (total bilirubin >10 mg/dL), gastrointestinal adverse events, cardiovascular adverse events, renal adverse events, and those adverse events that were related to liver function or infections. *Included four cases of anaemia, three cases of infection, three cases of hyperbilirubinaemia, two cases of hepatic decompensation, and one case of hepatocellular carcinoma. †Two deaths were due to multiple organ failure (one as a result of choledocholithiasis leading to sepsis; one as a result of acute kidney injury following resection of hepatocellular carcinoma), one was due to hepatopulmonary syndrome as a result of pneumonia, one was due to a car accident, one was due to lymphoma, and one sudden death of unknown cause. ‡Included variceal haemorrhage.

Table 3: Adverse events in all patients and by Child-Pugh score

<table>
<thead>
<tr>
<th>Adverse event leading to discontinuation of study drugs</th>
<th>Child-Pugh A (n=695)</th>
<th>Child-Pugh B (n=38)</th>
<th>All patients (n=734)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any adverse event</td>
<td>149 (21%)</td>
<td>17 (45%)</td>
<td>166 (23%)</td>
</tr>
<tr>
<td>Adverse event leading to discontinuation of study drugs</td>
<td>21 (3%)</td>
<td>4 (11%)</td>
<td>25 (3%)</td>
</tr>
<tr>
<td>Death</td>
<td>4 (1%)</td>
<td>2 (5%)</td>
<td>6 (1%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Most common adverse events of special interest</th>
<th>Child-Pugh A (n=695)</th>
<th>Child-Pugh B (n=38)</th>
<th>All patients (n=734)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthenia</td>
<td>34 (5%)</td>
<td>2 (5%)</td>
<td>36 (5%)</td>
</tr>
<tr>
<td>Haemoglobin concentration &lt;8 g/dL</td>
<td>17 (2%)</td>
<td>1 (3%)</td>
<td>18 (2%)</td>
</tr>
<tr>
<td>Infection</td>
<td>8 (1%)</td>
<td>3 (8%)</td>
<td>11 (1%)</td>
</tr>
<tr>
<td>Total bilirubin concentration &gt;10 mg/dL</td>
<td>5 (1%)</td>
<td>3 (8%)</td>
<td>8 (1%)</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>7 (1%)</td>
<td>0</td>
<td>7 (1%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>6 (1%)</td>
<td>0</td>
<td>6 (1%)</td>
</tr>
<tr>
<td>Hepatic decompensation†</td>
<td>3 (&lt;1%)</td>
<td>1 (3%)</td>
<td>4 (&lt;1%)</td>
</tr>
<tr>
<td>Renal failure</td>
<td>2 (&lt;1%)</td>
<td>0</td>
<td>2 (&lt;1%)</td>
</tr>
</tbody>
</table>

Table 3: Adverse events in all patients and by Child-Pugh score

Discussion

In this compassionate-use programme in patients with HCV genotype 1 or genotype 4 infection and cirrhosis, treatment with ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for 12 or 24 weeks resulted in a high proportion of patients achieving SVR12, similar to the proportions reported in clinical trials of these regimens. To our knowledge, this is the largest real-life study of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with cirrhosis. The concordance between the proportion of patients achieving a SVR12 in this study and in clinical trials provides reassurance that the reported efficacy of this treatment in clinical trials will translate to its use in routine clinical practice. The high proportion of patients achieving SVR12 in this study is similar to those reported in other real-life studies of ombitasvir, paritaprevir, and ritonavir, with dasabuvir, with or without ribavirin in patients with HCV genotype 1 infection and compensated cirrhosis.

The strength of this study is that the study population was large and representative of patients with HCV genotype 1 infection with compensated cirrhosis in real-life clinical practice in Italy. This study has some limitations. Patients were not randomly assigned treatment regimens or durations, and the choice of treatment, patient visits, and laboratory testing were at the investigators’ discretion. Moreover, the network of participating centres was established by AISF on the basis of the best expertise in HCV management, which may affect the external generalisability of our results. Furthermore, as efficacy and safety data were not provided by clinicians for all enrolled patients, it cannot be ruled out that the results of this study may slightly overestimate the efficacy and tolerability of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin.

At the time of this study, the label-recommended treatment of patients with genotype 1b infection and cirrhosis was a 12 week regimen of ombitasvir, paritaprevir, ritonavir, with dasabuvir plus ribavirin. The label-recommended treatment of this group of patients has been updated in the European Union (EU) to a 12 week regimen of ombitasvir, paritaprevir, and ritonavir, with dasabuvir without ribavirin, based on the finding that 60 (100%) of 60 patients with genotype 1b infection and compensated cirrhosis achieved SVR12 with this regimen in the phase 3b TURQUOISE-III trial.

The proportion of patients achieving SVR12 did not differ by ribavirin dose, but SVR12 was achieved in more patients with early virological response versus those without. This difference in the proportion of patients achieving a SVR12 by timing of virological response was predominantly driven by the subgroup of patients with HCV genotype 1b infection who were given ombitasvir, paritaprevir, and ritonavir, with dasabuvir plus ribavirin for 12 weeks, suggesting that longer duration treatment than 12 weeks might be
beneficial in patients with genotype 1b infection with late virological response. Despite these differences in the proportions of patients achieving a SVR12 between subgroups, the percentages were generally high (>90%). In patients who achieved a SVR12, markers of liver function, including albumin and bilirubin, significantly improved at week 12 after treatment compared with baseline, suggesting that SVR12 is associated with improvement of liver function.

In this compassionate-use programme, ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin was generally well tolerated, with few patients who discontinued treatment due to adverse events. Few patients had severe anaemia, and blood transfusion and erythropoietin use was low. The rate of hepatic decompensation in this study was low (four [1%] of 734 patients), which is within the range for the previously reported annual risk of up to 6% for hepatic decompensation in patients with HCV infection and compensated cirrhosis.19,20

Increases in bilirubin concentrations reported in our study are consistent with those described in previous safety analyses of ombitasvir, paritaprevir, and ritonavir, with dasabuvir, with or without ribavirin.21 Increases in bilirubin concentrations reported in previous analyses were predominately indirect and related to the inhibition of the bilirubin transporters organic anion transporter polypeptide (OATP) 1B1 and 1B3 by paritaprevir and to ribavirin-induced haemolysis.21 These increases in bilirubin concentration generally resolved and were not associated with increases in serum ALT.19 Increases in bilirubin concentrations seen in our study are therefore probably due to inhibition of the bilirubin transporters OATP1B1 and 1B3 by paritaprevir and ribavirin-induced haemolysis, rather than hepatotoxicity caused by ombitasvir, paritaprevir, and ritonavir, plus dasabuvir treatment.

Estimated creatinine clearance decreased slightly during treatment with ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin. This effect is consistent with that shown in patients with normal renal function (estimated glomerular filtration rate [eGFR] >90 mL/min per 1.73 m²) in previous safety analyses of ombitasvir, paritaprevir, and ritonavir, with dasabuvir plus ribavirin in phase 2 and 3 clinical trials.22 Conversely, mean eGFR increased in patients with baseline renal impairment.12,19 There were too few patients with baseline renal impairment to establish whether the same effect was present in our study.

More adverse events occurred in patients with Child-Pugh B cirrhosis compared with those with Child-Pugh A cirrhosis, although the number of patients with Child-Pugh B cirrhosis in this study was low. At the time of this compassionate-use programme, other HCV treatment regimens without protease inhibitors were not available. After enrolment in this compassionate use programme was closed, guidance for the use of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with Child-Pugh B was changed, and ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and ombitasvir, paritaprevir, and ritonavir are not recommended in patients with Child-Pugh B cirrhosis in the EU at present.21 Our data confirm the European Medicines Agency’s recommendation not to use these regimens in patients with Child-Pugh B cirrhosis.

In conclusion, data collected in this compassionate-use programme suggest that the efficacy and safety profiles of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 infection and advanced, compensated cirrhosis in a real-world setting are the same as those from clinical trials. Treatment of this population of patients is a high priority.

Contributors
All authors take full responsibility for the study design, data analysis and interpretation, and preparation of the manuscript; were involved in planning the analysis and drafting the manuscript; and approved the final draft manuscript.

Declaration of interests
SP has participated on advisory boards or has been a speaker for Gilead, AbbVie, Janssen, Bristol-Myers Squibb, MSD, and Roche. AAG reports grants from Gilead; and has participated on advisory boards and has been a speaker for Gilead, AbbVie, Janssen, MSD, and Bristol-Myers Squibb. AA is a consultant for or has received research funding from Gilead, Roche, Bristol-Myers Squibb, Janssen, AbbVie, and MSD. AAN reports grants and personal fees from Gilead, Bristol-Myers Squibb, ViV Healthcare, AbbVie, Janssen, Ciag, and Merck. RB has acted as an adviser or received speaker’s fees from AbbVie, Gilead, Janssen-Cilag, MSD, and Roche. SB reports consulting fees from Gilead, Janssen, Roche, and MSD. AC has been a speaker or has participated on advisory boards for Gilead, AbbVie, Bristol-Myers Squibb, and MSD. GBG has been a speaker or advisor for AbbVie, Gilead, Janssen, Bristol-Myers Squibb, and MSD. EGG reports consulting fees from research grants from, participation on advisory boards for, and is on the speaker’s bureau for AbbVie, Bayer, Bristol-Myers Squibb, Cilag, MSD, and Novartis. VM is an adviser for AbbVie. CFP reports grants from, has been a speaker for, or has participated in advisory boards for Gilead, AbbVie, Janssen, Bristol-Myers Squibb, and MSD. MP reports grants from Gilead, ViV Healthcare, and MSD; and personal fees for temporary scientific advice or talks in own events from AbbVie, Roche, and MSD. GR reports grants from Gilead, and MSD. GBG has been a speaker or advisor for AbbVie, Bayer, Bristol-Myers Squibb, Cilag, GlaxoSmithKline, Janssen Cilag, MSD, and Novartis. VM is an adviser for AbbVie. CFP reports grants from, has been a speaker for, or has participated in advisory boards for Gilead, AbbVie, Janssen, Bristol-Myers Squibb, and MSD. MP reports grants from Gilead, ViV Healthcare, and MSD; and personal fees for temporary scientific advice or talks in own events from AbbVie, Roche, Diagnostics, MSD, and MSD. MP reports grants from Gilead, and ViV Healthcare. GR reports grants from Gilead, and MSD; and has been a speaker or participated in advisory boards for Gilead, AbbVie, Janssen, Roche, Bristol-Myers Squibb, and MSD. MR has been a speaker or participated on advisory boards for Gilead, AbbVie, Bristol-Myers Squibb, and MSD. FCS has received grants, has been a speaker, or participated on advisory boards for Gilead, AbbVie, Janssen, Roche, and MSD. MP reports grants from Gilead, ViV Healthcare, and MSD; and has been a speaker or participated in advisory boards for Gilead, AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, and Roche; and has been a speaker and done teaching for AbbVie, GlaxoSmithKline, and Novartis. AC reports research grants, participation on advisory boards, and is a speaker for Gilead, AbbVie, Janssen, Bristol-Myers Squibb, and MSD. PR, SM, LP, MMa, AA, MM, and ALZ declare no competing interests.

Acknowledgments
The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies or the committees or working parties of the regulatory agencies the authors work for. Medical writing support was provided by Andrew Kerr of Medical Expressions and funded by Dipartimento Biomedico of Medicina Interna e Specialistica dell’Università di Palermo.
References


